Close Menu

NEW YORK – Horizon Discovery announced preliminary FY2019 revenues on Tuesday, reporting that it expects revenues for the year to rise approximately 7 percent year over year.

Reported revenues for FY2019, including continuing and discontinued operations, are expected to be approximately €62.9 million ($69.5 million), up from €58.7 million in 2018. On a constant currency basis, the company is expecting revenues of €61.2 million, an increase of approximately 4 percent from 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.